Huntingtin-lowering strategies for Huntington’s disease

References

• Rawlins MD, Wexler NS, Wexler AR, et al. The prevalence of Huntington’s disease. Neuroepidemiology. 2016;46(2):144–153.
   PubMed Web of Science ®Google Scholar
• Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004 Oct 14;431(7010):805–810.
   PubMed Web of Science ®Google Scholar
• Bauerlein FJB, Saha I, Mishra A, et al. In situ architecture and cellular interactions of polyQ inclusions. Cell. 2017 Sep 21;171(1):179–187 e10.
   PubMed Web of Science ®Google Scholar
• Jimenez-Sanchez M, Licitra F, Underwood BR, et al. Huntington’s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med. 2017 Jul 5;7(7):a024240.
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell. 2000 Mar 31;101(1):57–66.
   PubMed Web of Science ®Google Scholar
• Wang N, Gray M, Lu XH, et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington’s disease. Nat Med. 2014 May;20(5):536–541. .
   PubMed Web of Science ®Google Scholar
• Ferrari Bardile C, Garcia-Miralles M, Caron NS, et al. Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. Proc Natl Acad Sci U S A. 2019 May 7;116(19):9622–9627.
   PubMed Web of Science ®Google Scholar
• Wood TE, Barry J, Yang Z, et al. Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington’s disease mouse model. Hum Mol Genet. 2019 Feb 1;28(3):487–500.
   PubMed Web of Science ®Google Scholar
• Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. Embo J. 2000 Nov 1;19(21):5720–5728.
   PubMed Web of Science ®Google Scholar
• Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self-digestion. Nature. 2008 Feb 28;451(7182):1069–1075.
   PubMed Web of Science ®Google Scholar
• Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004 Jun;36(6):585–595.
   PubMed Web of Science ®Google Scholar
• Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006 Oct 19;443(7113):780–786.
   PubMed Web of Science ®Google Scholar
• Williams A, Sarkar S, Cuddon P, et al. Novel targets for Huntington’s disease in an mTOR-independent autophagy pathway. Nat Chem Biol. 2008 May;4(5):295–305. .
   PubMed Web of Science ®Google Scholar
• Sarkar S, Floto RA, Berger Z, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol. 2005 Sep 26;170(7):1101–1111.
   PubMed Web of Science ®Google Scholar
• Ravikumar B, Berger Z, Vacher C, et al. Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet. 2006 Apr 1;15(7):1209–1216.
   PubMed Web of Science ®Google Scholar
• Rubinsztein DC, Gestwicki JE, Murphy LO, et al. Potential therapeutic applications of autophagy. Nat Rev Drug Discov. 2007 Apr;6(4):304–312. .
   PubMed Web of Science ®Google Scholar
• Shibata M, Lu T, Furuya T, et al. Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1. J Biol Chem. 2006 May 19;281(20):14474–14485.
   PubMed Web of Science ®Google Scholar
• Zheng S, Clabough EB, Sarkar S, et al. Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice. PLoS Genet. 2010 Feb 5;6(2):e1000838.
   PubMed Web of Science ®Google Scholar
• Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet. 2002 May 1;11(9):1107–1117.
   PubMed Web of Science ®Google Scholar
• Siddiqi FH, Menzies FM, Lopez A, et al. Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing. Nat Commun. 2019 Apr 18;10(1):1817.
   PubMedGoogle Scholar
• Li Z, Wang C, Wang Z, et al. Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds. Nature. 2019 Nov;575(7781):203–209.
   PubMed Web of Science ®Google Scholar
• Sakamoto KM, Kim KB, Kumagai A, et al. Protacs: chimeric molecules that target proteins to the Skp1-cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8554–8559.
   PubMed Web of Science ®Google Scholar
• Tomoshige S, Nomura S, Ohgane K, et al. Discovery of small molecules that induce the degradation of huntingtin. Angew Chem Int Ed Engl. 2017 Sep 11;56(38):11530–11533.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin lowering strategies for disease modification in Huntington’s disease. Neuron. 2019 May 22;102(4):899.
   PubMed Web of Science ®Google Scholar
• Vachey G, Deglon N. CRISPR/Cas9-mediated genome editing for Huntington’s disease. Methods Mol Biol. 2018;1780:463–481.
   PubMedGoogle Scholar
• Hogarth P, Lovrecic L, Krainc D. Sodium phenylbutyrate in Huntington’s disease: a dose-finding study. Mov Disord. 2007 Oct 15;22(13):1962–1964.
   PubMed Web of Science ®Google Scholar
• Bennett CF, Krainer AR, Cleveland DW. Antisense oligonucleotide therapies for neurodegenerative diseases. Annu Rev Neurosci. 2019 Jul;8(42):385–406.
   Google Scholar
• Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron. 2012 Jun 21;74(6):1031–1044.
   PubMed Web of Science ®Google Scholar
• Caron NS, Dorsey ER, Hayden MR. Therapeutic approaches to Huntington disease: from the bench to the clinic. Nat Rev Drug Discov. 2018 Oct;17(10):729–750.
   PubMed Web of Science ®Google Scholar
• Leavitt BR, Kordasiewicz HB, Schobel SA. Huntingtin-lowering therapies for Huntington disease: a review of the evidence of potential benefits and risks. JAMA Neurol. 2020 Mar 23;77:764. .
   PubMed Web of Science ®Google Scholar
• Grondin R, Kaytor MD, Ai Y, et al. Six-month partial suppression of huntingtin is well tolerated in the adult rhesus striatum. Brain. 2012 Apr;135(Pt 4):1197–1209. .
   PubMedGoogle Scholar
• Burrus CJ, McKinstry SU, Kim N, et al. Striatal projection neurons require huntingtin for synaptic connectivity and survival. Cell Rep. 2020 Jan 21;30(3):642–657 e6.
   PubMed Web of Science ®Google Scholar
• Poplawski GHD, Kawaguchi R, Van Niekerk E, et al. Injured adult neurons regress to an embryonic transcriptional growth state. Nature. 2020 May;581(7806):77–82. .
   PubMed Web of Science ®Google Scholar
• Smith AV, Tabrizi SJ. Therapeutic antisense targeting of huntingtin. DNA Cell Biol. 2020 Feb;39(2):154–158.
   PubMed Web of Science ®Google Scholar
• Stanek LM, Yang W, Angus S, et al. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington’s disease. J Huntingtons Dis. 2013;2(2):217–228.
   PubMedGoogle Scholar
• Southwell AL, Kordasiewicz HB, Langbehn D, et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington’s disease. Sci Transl Med. 2018 Oct 3;10(461):eaar3959.
   PubMed Web of Science ®Google Scholar
• Rodrigues FB, Wild EJ. Huntington’s disease clinical trials corner: april 2020. J Huntingtons Dis. 2020 Apr 2;9:185–197.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting huntingtin expression in patients with Huntington’s disease. N Engl J Med. 2019 Jun 13;380(24):2307–2316.
   PubMed Web of Science ®Google Scholar
• Liu JP, Zeitlin SO. Is huntingtin dispensable in the adult brain? J Huntingtons Dis. 2017;6(1):1–17.
   PubMed Web of Science ®Google Scholar
• Steven H, Daniel C, Mary E, et al. Multicenter, randomized, double-blind placebo-controlled phase 1b/2a studies of WVE-120101 and WVE-120102 in patients with Huntington’s disease. Neurology. 2017. 88(16 Supplement):P2.006.
   Google Scholar
• 2019. Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease [press release].
   Google Scholar
• Caron NS, Southwell AL, Brouwers CC, et al. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Res. 2020 Jan 10;48(1):36–54.
   PubMed Web of Science ®Google Scholar
• Evers MM, Miniarikova J, Juhas S, et al. AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington’s disease minipig model. Mol Ther. 2018 Sep 5;26(9):2163–2177.
   PubMed Web of Science ®Google Scholar
• Stanek LM, Sardi SP, Mastis B, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington’s disease. Hum Gene Ther. 2014 May;25(5):461–474. .
   PubMed Web of Science ®Google Scholar
• Hadaczek P, Stanek L, Ciesielska A, et al. Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington’s disease. Mol Ther Methods Clin Dev. 2016;3:16037.
   PubMed Web of Science ®Google Scholar
• 2017. Voyager Therapeutics Selects Lead Clinical Candidates for Huntington’s Disease [press release].
   Google Scholar
• Vitet H, Brandt V, Saudou F. Traffic signaling: new functions of huntingtin and axonal transport in neurological disease. Curr Opin Neurobiol. 2020 May 11;63:122–130. .
   PubMed Web of Science ®Google Scholar
• Rubinsztein DC, Orr HT. Diminishing return for mechanistic therapeutics with neurodegenerative disease duration?: there may be a point in the course of a neurodegenerative condition where therapeutics targeting disease-causing mechanisms are futile. Bioessays. 2016 Oct;38(10):977–980.
   PubMed Web of Science ®Google Scholar
• Zu T, Duvick LA, Kaytor MD, et al. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci. 2004 Oct 6;24(40):8853–8861.
   PubMed Web of Science ®Google Scholar
• Zeun P, Scahill RI, Tabrizi SJ, et al. Fluid and imaging biomarkers for Huntington’s disease. Mol Cell Neurosci. 2019 Jun;97:67–80.
   PubMed Web of Science ®Google Scholar
• Anil M, Mason SL, Barker RA. The clinical features and progression of late-onset versus younger-onset in an adult cohort of Huntington’s disease patients. J Huntingtons Dis. 2020 Jul 14:1–8. DOI:10.3233/JHD-200404.
   PubMed Web of Science ®Google Scholar
• Lakra P, Aditi K, Agrawal N. Peripheral expression of mutant huntingtin is a critical determinant of weight loss and metabolic disturbances in Huntington’s disease. Sci Rep. 2019 Jul 12;9(1):10127.
   PubMedGoogle Scholar
• Rodinova M, Krizova J, Stufkova H, et al. Deterioration of mitochondrial bioenergetics and ultrastructure impairment in skeletal muscle of a transgenic minipig model in the early stages of Huntington’s disease. Dis Model Mech. 2019 Jul 26;12(7):dmm038737.
   PubMed Web of Science ®Google Scholar